NCT01405937View on ClinicalTrials.gov

Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)

PHASE3CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

August 29, 2011

Primary Completion Date

February 26, 2013

Study Completion Date

March 12, 2013

Conditions
Hepatitis C, Chronic
Interventions
DRUG

vaniprevir

vaniprevir capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks

BIOLOGICAL

peg-IFN

peg-IFN 1.5 µg/kg once per week, subcutaneously (SC) for 24 weeks

DRUG

ribavirin

Capsules containing 200 mg ribavirin, orally, 3 to 5 capsules, dosage based on participant weight (600 mg/day to 1000 mg/day), for 24 weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01405937 - Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044) | Biotech Hunter | Biotech Hunter